Jabbour, Elias, Ottmann, Oliver  ORCID: https://orcid.org/0000-0001-9559-1330, Deininger, Michael and Hochhaus, Andreas
2014.
Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.
Haematologica
99
(1)
, pp. 7-18.
10.3324/haematol.2013.087171
|
Preview |
PDF
- Published Version
Available under License Creative Commons Attribution. Download (416kB) | Preview |
Abstract
The phosphoinositide 3-kinase pathway represents an important anticancer target because it has been implicated in cancer cell growth, survival, and motility. Recent studies show that PI3K may also play a role in the development of resistance to currently available therapies. In a broad range of cancers, various components of the phosphoinositide 3-kinase signaling axis are genetically modified, and the pathway can be activated through many different mechanisms. The frequency of genetic alterations in the phosphoinositide 3-kinase pathway, coupled with the impact in oncogenesis and disease progression, make this signaling axis an attractive target in anticancer therapy. A better understanding of the critical function of the phosphoinositide 3-kinase pathway in leukemias and lymphomas has led to the clinical evaluation of novel rationally designed inhibitors in this setting. Three main categories of phosphoinositide 3-kinase inhibitors have been developed so far: agents that target phosphoinositide 3-kinase and mammalian target of rapamycin (dual inhibitors), pan-phosphoinositide 3-kinase inhibitors that target all class I isoforms, and isoform-specific inhibitors that selectively target the α, -β, -γ, or -δ isoforms. Emerging data highlight the promise of phosphoinositide 3-kinase inhibitors in combination with other therapies for the treatment of patients with hematologic malignancies. Further evaluation of phosphoinositide 3-kinase inhibitors in first-line or subsequent regimens may improve clinical outcomes. This article reviews the role of phosphoinositide 3-kinase signaling in hematologic malignancies and the potential clinical utility of inhibitors that target this pathway.
| Item Type: | Article |
|---|---|
| Date Type: | Published Online |
| Status: | Published |
| Schools: | Schools > Medicine |
| Subjects: | R Medicine > R Medicine (General) |
| Publisher: | Ferrata Storti Foundation |
| ISSN: | 0390-6078 |
| Date of First Compliant Deposit: | 12 December 2016 |
| Date of Acceptance: | 4 October 2013 |
| Last Modified: | 03 May 2023 21:09 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/96803 |
Citation Data
Cited 36 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
 |
Edit Item |
Dimensions
Dimensions